TG Therapeutics completes enrollment in Phase III UNITY-CLL trial

TG Therapeutics Inc. (NASDAQ:TGTX) completed enrollment in the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101) in combination with TGR-1202 (umbralisib) to treat chronic lymphocytic leukemia (CLL).

The open-label, international trial is comparing IV ublituximab and oral TGR-1202 alone or in combination vs. IV Gazyva obinutuzumab plus oral chlorambucil in patients with both treatment naïve and relapsed or refractory CLL. Patients receive ublituximab on days 1, 8 and 15 followed by maintenance infusions and TGR-1202 once daily. The primary endpoint is progression-free survival (PFS) and the secondary endpoint is overall response rate (ORR). The company has now enrolled more than 200 patients in each of the two combination arms...